OncLive TV

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

Matthew Frank, MD, PhD, discusses the rationale for investigating CD22-directed CAR-T cell therapy in adult patients with large B-cell lymphoma who relapsed after or were refractory to CD19-directed CAR T-cell therapy.

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

Sunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma. 

Ronan J. Kelly, MD, MBA, discusses the variety of clinical trials investigating immunotherapy with or without chemotherapy in patients with esophageal squamous cell carcinoma.

Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.

Petros Grivas, MD, PhD, discusses key baseline characteristics from the real-world PATRIOT II study of first-line avelumab maintenance therapy in metastatic urothelial cancer. 

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.

Carlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.

Siamak Daneshmand, MD, discusses findings from the interim analysis of cohort 3 of the multicohort phase 2 THOR-2 trial.

Eleni Efstathiou, MD, PhD, discusses second interim findings from a subgroup analysis of the phase 3 MAGNITUDE trial in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Michael B. Atkins, MD, discusses the treatment-free survival outcomes from cohort A of the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Srikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.

James J. Harding, MD, discusses the prevalence of TSC1 and TSC2 mutations in gastrointestinal cancer, and the need to develop a standard-of-care treatment for patients with these genetic alterations.

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.

Arya Mariam Roy, MBBS, discusses the effect of neoadjuvant chemotherapy on overall survival in patients with sarcomatoid muscle-invasive bladder cancer.

Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.

Prateek Gulhati, MD, PhD, discusses current treatment approaches in pancreatic cancer and strategies under investigation within the space.

Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.

Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.

Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.

Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.